接受伊米苷酶治疗的Ⅰ型戈谢病患者生存质量调查

OBJECTIVE: To investigate the living status and quality of life (QOL) in type1 Gaucher disease (GD1) patients who underwent long-term enzyme replacement therapy (ERT) and identify possible relevant factors affecting QOL. METHODS: Clinical data and SF-36 questionnaires were recorded in 22 adult GD1 patients under regular ERT at Peking Union Medical Colleague Hospital (PUMCH) from January 1995 to June 2017. RESULTS: 13 males and 9 females were included in this study. The current median age, age at diagnosis and initial time of ERT were 41 (24–52), 6 (1–38) and 26 (6–41) years respectively. Of these patients, 68.2% was living in less-developed regions, 86.4% were under college education, and 77.3% had personal annual income less than ¥30 000 RMB. Though after a median 16 (7–22) years of ERT, the QOL of GD1 patients was still significantly worse (P<0.05) compared with normal Chinese population based on SF-36 questionnaires. History of splenectomy was a negative factor of QOL, mainly in physical health (P<0.05). Patients could get benefit from early start of ERT in both physical and mental health (P<0.05). Mental health was not affected by history of splenectomy and related bone diseases. CONCLUSION: Most adult GD1 patients at PUMCH reside in less-developed regions and have low levels of education and annual income. History of splenectomy and time to start ERT are two important factors affecting QOL. Chinese adult GD1 patients are associated with reduced QOL, even after long-term ERT.